← All trials
NCT03932136
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2018
- Primary completion
- Sep 30, 2020
- Completion date
- Dec 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Central South UniversityCollaborator
- University of California, San DiegoOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Jiao Tong UniversityStudy director
- Jiao Tong UniversityReponsible party - principal investigator
- Guangzhou Medical UniversityCollaborator
- Suzhou Psychiatric HospitalCollaborator
- Shenzhen Fushan Biotech Co., Ltd.Collaborator
- Shenzhen Fushan Biotech Co., Ltd.Overall official - principal investigator
- Shanghai Xuhui District Mental Health CenterCollaborator
- Shanghai Pudong Nanhui Mental Health CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.